title: Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age.
abstract: A pooled analysis of data from four vaccination studies conducted in Europe was undertaken to assess the immunogenicity of Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals) when administered in a total of 702 healthy infants at 3, 5 and 11-12 months of age. One month after dose 2, between 96.3% and 100% of subjects had seroprotective antibodies against diphtheria, tetanus, hepatitis B and poliovirus types 1, 2 and 3; 91.7% against Hib and ≥99.0% were seropositive for each pertussis antigen. One month after the third dose, 98.9-100% of subjects were seroprotected/seropositive for all vaccine antigens. Geometric mean antibody concentrations/titres for each vaccine antigen increased by 6.7-52.9 fold after the third vaccine dose. No serious adverse events in DTPa-HBV-IPV/Hib recipients were vaccine related. Infanrix™ hexa induces an adequate immune response after 2-dose primary plus booster doses when administered according to a 3, 5 and 11 months schedule.
authors.affiliation: GlaxoSmithKline Biologicals, 20 Fleming Avenue, Wavre, Belgium. Olivier.x.Van-Der-Meeren@gskbio.com
authors.forename: Olivier
authors.initials: O
authors.lastname: Van Der Meeren
authors.forename: Sherine
authors.initials: S
authors.lastname: Kuriyakose
authors.forename: Devayani
authors.initials: D
authors.lastname: Kolhe
authors.forename: Karin
authors.initials: K
authors.lastname: Hardt
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D004165:Diphtheria / Q000276:immunology / Q000517:prevention & control; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D005260:Female; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007223:Infant; D008297:Male; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D013742:Tetanus / Q000276:immunology / Q000517:prevention & control; D013997:Time Factors; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined